Literature DB >> 15104012

[Five years of proton therapy of eye neoplasms at the Hahn-Meitner Institute, Berlin].

Jens Heufelder1, Dino Cordini, Hermann Fuchs, Jürgen Heese, Heinrich Homeyer, Heinz Kluge, Hans Morgenstern, Stefan Höcht, Martin Nausner, Nikolaos E Bechrakis, Wolfgang Hinkelbein, Michael H Foerster.   

Abstract

Eye tumors (choroidal melanomas, iris melanomas, and choroidal hemangiomas) are being treated with 68 MeV protons since 1998 at the Ion Beam Laboratory of the Hahn-Meitner Institute of Berlin (Germany's first proton therapy center), in cooperation with the Charité University Hospital in Berlin, Campus Benjamin Franklin. The proton beam, generated via a combination of Van de Graaff accelerator and cyclotron, is prepared by passive shaping for conformal tumor irradiation. A digital X-ray verification of the tumor location with the patient in sitting position limits the position uncertainties to a maximum of 0.3 mm. The treatment planning is performed using the program EYEPLAN. OCTOPUS, a CT-based planning program developed in cooperation with the German Cancer Research Center of Heidelberg, is under pre-clinical testing. Thus far, more than 400 patients have been irradiated. The first results are comparable to those obtained in other proton therapy centers. At the end of 2002, the University Hospital of Essen has also become a cooperation partner of the Hahn-Meitner Institute.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104012     DOI: 10.1078/0939-3889-00190

Source DB:  PubMed          Journal:  Z Med Phys        ISSN: 0939-3889            Impact factor:   4.820


  4 in total

1.  Quantification of radiation retinopathy after beam proton irradiation in centrally located choroidal melanoma.

Authors:  Catharina Busch; Julia Löwen; Daniel Pilger; Ira Seibel; Jens Heufelder; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-12       Impact factor: 3.117

2.  Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.

Authors:  Aline I Riechardt; Daniel Pilger; Dino Cordini; Ira Seibel; Enken Gundlach; Annette Hager; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-18       Impact factor: 3.117

3.  Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.

Authors:  Alexander Böker; Daniel Pilger; Dino Cordini; Ira Seibel; Aline I Riechardt; Antonia M Joussen; Nikolaos E Bechrakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-16       Impact factor: 3.117

Review 4.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.